Therefore, based on our results finding that SerpinB2 alters cell invasion and invadopodia-like structure protrusion, we propose the up-regulation of SerpinB2 as a strategy to overcome gefitinib resistance in NSCLC cells. The gene discussed is SERPINB2; the disease is non-small cell lung carcinoma.